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Abstract
Although endoscopic submucosal dissection (ESD) is 
now accepted for treatment of early gastric cancers 
(EGC) with negligible risk of lymph node (LN) metas-
tasis, ESD for intramucosal undifferentiated type EGC 
without ulceration and with diameter ≤ 2 cm is re-
garded as an investigational treatment according to the 
Japanese gastric cancer treatment guidelines. This con-
sideration was largely based on the analysis of surgi-
cally resected EGCs that contained undifferentiated type 
EGCs; however, results from several institutes showed 
some discrepancies in sample size and incidence of LN 
metastasis. Recently, some reports about the safety and 
efficacy of ESD for undifferentiated type EGC meeting 
the expanded criteria have been published. Nonethe-
less, only limited data are available regarding long-term 
outcomes of ESD for EGC with undifferentiated histolo-
gy so far. At the same time, endoscopists cannot ignore 
the patients’ desire to guarantee quality of life after 
the relatively non-invasive endoscopic treatment when 
compared to conventional surgery. To satisfy the needs 
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of patients and provide solid evidence to support ESD 
for undifferentiated EGC, we need more delicate tools 
to predict undetected LN metastasis and more data that 
can reveal predictive factors for LN metastasis. 
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Endoscopic submucosal dissection (ESD) for 
intramucosal undifferentiated (UD) type early gastric 
cancer (EGC) without ulceration and with diameter 
≤ 2 cm is regarded as an investigational treatment 
according to the Japanese gastric cancer treatment 
guidelines. In contrast, the controversial results about 
the safety of ESD for UD-EGC fulfilling the criteria have 
been reported and a little is known about the long-term 
outcomes. Therefore, in this review, we focused on the 
safety and therapeutic efficacy of ESD for UD-EGC with 
reference to risks for lymph node metastasis within the 
proposed criteria as well as the short-term and long-
term outcomes of ESD for UD-EGC.
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INTRODUCTION
Early gastric cancer (EGC) is defined as gastric cancer 
that is confined to the mucosa or submucosa, irrespective 
of  the presence of  regional lymph node (LN) metasta-
ses[1]. In the Eastern hemisphere, up to 70% of  all gastric 
cancers are diagnosed as EGCs (due to mass population 
screening)[2-4], whereas in the Western hemisphere, the 
rate of  gastric cancers identified as EGCs accounts for 
only about 15%[5,6]. EGC reveals a favorable prognosis 
compared with advanced gastric cancer, with 5-year sur-
vival rates being in excess of  90% to 95%, based on Ko-
rea, Japan, and European data[7-13].
In Eastern countries, endoscopic resection (ER), 
including endoscopic mucosal resection (EMR) and en-
doscopic submucosal dissection (ESD), has been widely 
accepted as a minimally invasive treatment for EGC with 
a negligible risk of  LN metastasis[14-18]. Recently, consid-
erable data have also been reported from the Western 
world as ER is gaining wide acceptance[19-21]. Tumors in-
dicated for ER as a standard treatment are differentiated-
type adenocarcinomas without ulceration, of  which the 
depth of  invasion is clinically diagnosed as mucosal layer 
and the diameter is ≤ 20 mm[22]. Gotoda et al[23] studied 
surgically resected specimens of  EGC and suggested the 
following four expanded indication criteria for endoscop-
ic treatment of  EGC without LN metastasis: (1) differen-
tiated intramucosal cancer without ulceration, regardless 
of  size; (2) differentiated intramucosal cancer with ulcer-
ation and diameter ≤ 30 mm; (3) differentiated minute 
submucosal penetrative cancer in diameter ≤ 30 mm; 
and (4) undifferentiated (UD) type intramucosal cancer 
without ulceration and diameter ≤ 20 mm. In particular, 
surgery was still considered in the UD-EGC meeting the 
expanded criteria because endoscopic en-bloc removal was 
sometimes difficult in this type of  tumors (Figure 1)[24,25]. 
However, Hirasawa et al[26] added to the body of  evidence 
that there is no LN metastasis in patients with UD-
EGC within the expanded criteria. This study revealed 
the 95%CI of  the calculated risk of  metastasis to nodes 
was 0%-0.96%, while the earlier study by Gotoda et al[23] 
showed that of  risk was 0%-2.6% due to small sample 
size (n = 141), which may potentially be inferior to the 
outcomes of  surgical resection.
Along these lines, the Japanese gastric cancer treat-
ment guidelines (2010, ver. 3) state that ER for these UD-
EGCs is regarded as an investigational treatment, and 
that ESD, not EMR, should be employed. In contrast, 
clinical practice guidelines, according to both National 
Comprehensive Cancer Network[27] and European Soci-
ety for Medical Oncology[28], do not yet recognize ER for 
EGCs meeting the expanded criteria as safe. Moreover, 
the controversial results about the safety of  ESD for 
UD-EGC fulfilling the criteria have been reported and a 
little is known about the long-term outcomes. Therefore, 
in this review, we focused on the safety and therapeutic 
efficacy of  ESD for UD-EGC with reference to risks for 
LN metastasis within the proposed criteria as well as the 
short-term and long-term outcomes of  it.
PREOPERATIVE ASSESSMENT OF LN 
METASTASIS 
The most important factor concerning endoscopic treat-
ment with curative intent is the prediction of  regional LN 
metastasis before treatment[22,27,28]. Reported rates of  LN 
metastasis in EGC range from 5.7% to 20% based on 
the analysis of  surgically resected specimen of  EGC[29-34]. 
UD-EGC demonstrates 4.2% to 4.9% and 19.0% to 
23.8%of  LN metastasis in the mucosal and submucosal 
invasive tumors, respectively[23,26]. To date, no imaging 
modality has been proven to be consistently accurate in 
assessing LN metastasis in EGC[35,36]. Endoscopic ultra-
sound (EUS) is one of  most studied procedures for the 
locoregional staging of  gastric cancer. Reported sensitivi-
ties and specificities of  EUS to detect LN metastases 
in gastric cancers varied widely, between 16.7% and 
95.3%, and between 48.4% and 100%, respectively[35]. 
EUS demonstrated a moderate accuracy that seems to 
describe advanced T stage (T3 and T4) better than N or 
less advanced T stage[37,38]. Although a clinically relevant 
benefit of  EUS to distinguish intramucosal lesions from 
submucosal lesions should be further improved[39], EUS 
is an important imaging modality for preoperative as-
sessment to exclude LN metastasis as well as to confirm 
deeper wall invasion including the proper muscle layer. 
Nevertheless, we should consider that UD histology 
would cause under-diagnosis and affect the accuracy of  
EUS compared to the differentiated histology[40]. 
In addition to the diagnostic role of  magnifying en-
doscopy with narrow-band imaging (ME-NBI) for de-
termining tumor margin in EGC[41,42], ME-NBI has been 
suggested as a supporting tool for the assessment of  
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                Depth Mucosal cancer Submucosal cancer
No ulceration Ulceration SM1 ≤ SM2
Histology ≤ 20 mm > 20 mm ≤ 30 mm > 30 mm ≤ 30 mm Any size
Differentiated
Undifferentiated
Absolute indications for EMR or ESD Expanded indications for ESD
Consider surgery Surgery (Gastrectomy and lymph node dissection)
Figure 1  Absolute and expanded indication for endoscopic mucosal resection and endoscopic submucosal dissection for early gastric cancer. SM1: Tu-
mor invasion into the upper third of the submucosa (≤ 500 μm); SM2: Tumor invasion into the mid-third of the submucosa (> 500 μm). EMR: Endoscopic mucosal 
resection; ESD: Endoscopic submucosal dissection.
invasion depth in EGC[43-46]. In contrast to the usefulness 
of  ME-NBI for evaluating invasive depth in esophageal 
or colon cancer[47,48], the utility of  ME-NBI for determin-
ing invasion depth in EGC is not conclusive, because the 
invasive tumor is often not exposed at the surface and the 
mucosal structure remains, even when cancer invades the 
submucosa. Therefore, it is difficult to estimate reliably 
the depth of  invasion by surface appearance[49]. ME-NBI 
should also distinguish findings suggestive of  submuco-
sal invasion from those indicative of  the UD histologic 
type[44,45]. The findings of  a nonstructural pattern in the 
neoplastic lesion of  the stomach on ME[45] or no surface 
pattern and sparse microvessels (markedly distorted, 
isolated, heterogeneous) or with avascular areas on ME-
NBI[44] are indicative of  undifferentiated type adenocarci-
noma or differentiated cancer with deep submucosal inva-
sion. In contrast, ME-NBI images of  UD-EGC were very 
closely related to the histopathological findings in other 
study[50], and therefore, this imaging tool can be useful 
in the pretreatment assessment of  the histopathological 
patterns of  cancer development and the lateral extent of  
UD-EGC. Thus, the role of  ME-NBI in differentiation 
of  histologic types in addition to invasive depth should be 
validated through further prospective studies.
Other imaging modalities including abdominal ul-
trasound (AUS), computed tomography (CT), magnetic 
resonance imaging (MRI), and positron emission tomog-
raphy (PET) achieved limited success to stage preopera-
tive LN status[35,36]. A meta-analysis by Seevaratnam et al[36] 
showed that imaging modalities range in overall accuracy 
from 53.4% (MRI) to 68.1% (AUS), in sensitivity from 
40.3% (PET) to 85.3% (MRI), and in specificity from 
75.0% (MRI) to 97.7% (PET), with no significant differ-
ences between modalities. To date, there are no clinically 
relevant imaging tools to detect the submucosal invasion 
and the LN metastasis in EGC that are critical conditions 
for determining proper candidates for ER.
RISK FACTORS FOR LN METASTASIS 
AND PROPOSED CRITERIA FOR ESD
Because currently available imaging modalities fail to ac-
curately evaluate nodal status, endoscopic resectability ac-
cording to nodal status in EGC and subsequent curability 
are still determined by means of  the presence or absence 
of  certain tumor characteristics which were obtained 
from the analysis of  surgically resected EGC. According 
to the Japanese gastric cancer treatment guidelines[22], the 
main risk factors predictive of  LN metastasis in EGC 
are histologic type, depth of  invasion, ulceration, size, 
and lymphovascular invasion largely based on two large-
scale datasets[23,26]. These factors consist of  absolute and 
expanded indications as well as curability of  ER with en 
bloc resection and negative lateral/vertical margin (Table 
1)[22,51]. A meta-analysis by Kwee et al[52] identified the 
characteristics related to LN metastasis in EGC, including 
age, gender, location, size, macroscopic type, ulceration, 
histologic type in accordance with Japanese and Lauren 
classification, lymphovascular invasion, submucosal vas-
cularity, a proliferating cell nuclear antigen labeling index, 
a matrix metalloproteinase-9-positivity, a gastric mucin 
phenotype, and a vascular endothelial growth factor-C-
positivity. These factors revealed partially different cor-
relations with LN metastasis in intramucosal and submu-
cosal EGCs, respectively.
With regard to LN metastasis particularly in UD-
EGC, many recent studies investigated the risk factors 
and suggested their criteria for ER of  UD-EGC (Table 
2)[23,26,53-65]. The overall rates of  LN metastasis in UD-
EGC varied from 7.9% to 24.5%; however, the hetero-
geneous composition in subtypes of  UD histology in 
lesions from 15 studies should be taken into account. 
Size of lesion
Although the intramucosal lesions without ulceration and 
diameter ≤ 20 mm have been considered as rational cri-
teria for ESD in UD-EGC by Japanese researchers[23,26], 
different ER criteria have also been suggested with vari-
ous standards in size, depth of  invasion, and presence of  
ulcerative finding[53-65]. Concerning lesion size, a majority 
of  recent studies (11/15, 73.3%) suggested that a diam-
eter of  20 mm to 30 mm would be the upper limit of  the 
size criterion for UD-EGC to be amenable to treatment 
with ESD; however, the remaining four studies proposed 
a diameter of  10 or 15 mm as the upper limit of  the cri-
terion, based on their results suggesting the possibility of  
LN metastasis even in smaller UD-EGC[54,60,64,65]. Debates 
over the size criterion were highlighted by several reports 
of  LN metastasis of  UD-EGCs within the expanded 
criteria, including a diameter ≤ 20 mm[31,66-70]. Moreover, 
the size discrepancy between pathologic size and en-
doscopic size should be resolved, because we can only 
determine the indications of  ER based on the endoscopi-
cally estimated size. While a previous study revealed that 
endoscopic visual estimation method was found to show 
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Table 1  Curability for endoscopic resection of early gastric 
cancer
Curability criteria
Curative 
resection
En bloc resection, no lateral and vertical margin 
positivity, no lymphovascular invasion
Intramucosal cancer, differentiated histology, size ≤ 
20 mm, No ulcerative finding
Curative 
resection for 
expanded 
indications
En bloc resection, no lateral and vertical margin 
positivity, no lymphovascular invasion
Intramucosal cancer, differentiated histology, size > 
20 mm, no ulcerative finding
Intramucosal cancer, differentiated histology, size ≤ 
30 mm, presence of ulcerative finding
SM 1 depth of invasion, differentiated histology, size 
≤ 30 mm, no ulcerative finding
Intramucosal cancer, undifferentiated histology, size 
≤ 20 mm, no ulcerative finding
Non-curative 
resection
 Any resection that does not satisfy one of the above 
criteria
Shim CN et al . ESD for undifferentiated type EGC
SM: Submucosa.
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for ER, were relatively small compared with other stud-
ies. More importantly, the majority of  recent studies 
reported the LN metastasis in a depth of  submucosal 
invasion[23,26,54,55,57,59,61-65].
Ulceration
Ulceration within the lesion is the representative finding 
with heterogeneity. More than moderate heterogeneity 
was identified at previous meta-analysis with possible ex-
planation for this heterogeneity due to the interobserver 
variability between studies for the assessment of  tumor 
ulcerations[52]. Furthermore, this may be due to the differ-
ent definitions in addition to the interobserver variability 
for the assessment of  ulcerations[52,67,75,80]. Though most 
of  the recent studies (13/15, 86.7%) did not consider the 
ulcer finding in their proposed criteria, patients with tu-
mor ulcerations had a significantly higher risk of  LN me-
tastasis in intramucosal EGC irrespective of  histological 
type at meta-analysis[52]. And ulcerous change decreases 
the accuracy of  EUS diagnosis for the invasive depth 
of  EGC[81]. Therefore, we do not consider ER for UD-
EGCs with ulceration as safe.
reliable agreement with pathologic measurements in 
EGC treated with ER[71], other earlier ESD series showed 
the mean size discrepancies ranged from 5.8 mm to 6.8 
mm, which are not negligible in ER for EGC[72,73]. In 
UD-EGC, the margins of  the lesion tend to be obscured 
compared to the differentiated histology, which was 
found to cause frequent margin failure of  ESD in our 
previous report[74]. Thus, a standard reliable measurement 
method is required through further prospective studies[75].
Submucosal invasion
Some studies suggest that a shallow submucosal inva-
sion is an acceptable depth of  invasion in ESD for 
UD-EGC[53,56,58,60]. However, this suggestion should be 
reserved until EUS is more reliable for determination of  
invasive depth, because there is a high chance of  endo-
sonographically underestimated depth of  invasion and 
subsequently higher vertical margin positivity in poorly-
differentiated EGC[40,74], in addition to the difficult assess-
ment of  depth of  invasion in UD-EGC[76-79]. Addition-
ally, the numbers of  enrolled UD-EGCs in these studies, 
suggesting a minute submucosal invasion as a criterion 
Table 2  Proposed criteria for endoscopic resection of undifferentiated type early gastric cancer
Study Year Country No. of 
patients with 
UD-EGC
No. of 
patients with 
PD/SRC/MC
LNM in 
UD-EGC, 
n  (%)
LNM in 
proposed 
criteria
Risk factors related to 
LNM in UD-EGC
Proposed criteria of ER for UD-EGC
Size, mm Depth of 
invasion
Ulcer LVI
Tong et al[53] 2011 China   193 81/102/7/31   46 (23.8) 0/72 Size, depth of invasion, 
LVI, Histologic type
NS or ≤ 20 M or SM NS No
Kim et al[54] 2011 South Korea   707 288/419/0 65 (9.2)   0/101 Size, depth of invasion, 
LVI, Age2
 153 M NS No
Li et al[55] 2010 China   108 85/16/7   16 (14.8) 0/25 Size, depth of invasion, 
LVI
20 M NS No
Park et al[56] 2009 South Korea   215 Only SRC 17 (7.9) 0/57 Depth of invasion, LVI 25 SM2 NS No
Kunisaki et al[57] 2009 Japan   573 182/378/13   74 (12.9) 0/85 Size, depth of invasion, 
LVI
20 M NS No
Hirasawa et al[26] 2009 Japan 3843 NA 504 (13.1)   0/310 Size, depth of invasion, 
LVI
20 M No No
Hanaoka et al[58] 2009 Japan   143 NA   35 (24.5) 0/41 Size, depth of invasion, 
LVI, Histologic type
30 ≤ 500 μm4 NS No5
Ye et al[59] 2008 South Korea   591 266/316/9   79 (13.4)   0/119 Size, depth of invasion, 
LVI
25 M NS No
Park et al[60] 2008 South Korea   234 Only PD   25 (21.6) 0/56 Size, depth of invasion, 
LVI
15 M or 
≤ 500 μm
NS No
Li et al[61] 2008 China     85 Only PD   12 (14.1) 0/25 Size, depth of invasion, 
LVI
20 M NS No
Li et al[62] 2008 South Korea   646 307/330/9 61 (9.4)   1/201 Size, depth of invasion, 
LVI
20 M NS No
Ha et al[63] 2008 South Korea   641 248/388/5 100 (15.6) 0/77 Size, depth of invasion, 
LVI, histologic type
20 M NS No
Hyung et al[64] 2004 South Korea   289 NA   43 (14.9) NA Size, depth of invasion, 
LVI, histologic type
15 M NS No
Abe et al[65] 2004 Japan   175 68/104/3   32 (18.3)      0/6 Size, LVI 10 M NS No
Gotoda et al[23] 2000 Japan 2341 NA 243 (10.4)   0/141 Size, depth of invasion, 
LVI, histologic type, 
ulcer, macroscopic type
20 M No No
1Three patients had EGCs with histology of undifferentiated adenocarcinoma; 2Young age less than 45 years was related to the lymph node metastasis of 
only poorly-differentiated carcinoma; 3Size criteria were ≤ 25 mm in poorly-differentiated adenocarcinomas and ≤ 15 mm in signet-ring cell carcinomas, 
respectively; 4The depth of invasion in proposed criteria was ≤ 500 μm or no more from the lower margin of the muscularis mucosae; 5Hanaoka et al also 
suggested the proportion of undifferentiated components < 50% as one of criteria. UD-EGC: Undifferentiated type early gastric cancer; PD: Poorly-differen-
tiated adenocarcinoma; SRC: Signet-ring cell carcinoma; MC: Mucinous carcinoma; LNM: Lymph node metastasis; ER: Endoscopic resection; LVI: Lympho-
vascular invasion; M: Mucosa; SM: Submucosa; NS: Not significant; NA: Not available.
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Lymphovascular invasion
Only the absence of  lymphovascular invasion was the cri-
terion included by all studies, which was consistent with 
the results of  a meta-analysis revealing that lymphatic 
tumor invasion is the strongest predictor for LN metas-
tasis in both mucosal and submucosal gastric cancer[52]. 
For this reason, EGCs with lymphovascular invasion in 
endoscopically resected specimen should be treated by 
further surgery[22]. However, the Japanese gastric can-
cer treatment guidelines are not based on the status of  
lymphovascular invasion. The lymphovascular invasion 
is involved in the decision of  curability of  ER, since its 
evaluation can only be available in specimens obtained 
by ER. Moreover, the determination of  lymphovascular 
invasion sometimes lacks objectivity possibly because of  
the inability to distinguish lymphatics from blood vessels 
on conventional hematoxylin-eosin staining[82]. Several 
studies suggested an endoscopic elevated macroscopic 
type[83] and a stromal cell-derived factor-1α as risk factors 
of  lymphovascular invasion[84] with reports of  usefulness 
of  immunohistochemical staining for detection[82,85,86]. 
Considering the importance of  lymphovascular invasion 
for prediction of  LN metastasis, prospective studies of  
preoperative prediction for lymphovascular invasion are 
warranted. 
CLINICAL CHARACTERISTICS
Clinical characteristics of  recent representative studies on 
ER for UD-EGC are summarized in Table 3[73,74,76,80,87-90]. 
All eight studies were analyzed retrospectively. The num-
bers of  lesions ranged from 46 to 103 lesions and were 
not large enough to elicit conclusive results. Six studies 
performed solely ESD[73,76,80,87,89,90] and the rest carried 
out both EMR and ESD[74,88]. Inclusion criteria of  these 
studies were based on the expanded criteria except those 
of  two studies by Kim et al[80] and Kang et al[73]. The study 
by Kim et al[80] included patients who refused surgery and 
were treated by ESD as an experimental treatment. The 
study by Kang et al[73] included patients with UD-EGC 
with ulceration. Submucosal invasion and ulcers were 
noted in 9.7%-19.6% and 1.0%-9.3% of  lesions satisfying 
the expanded criteria, respectively. The two studies that 
included patients who refused surgery and lesions with 
ulcerations in endoscopic finding showed relatively high 
submucosal invasion and ulceration rates. The inaccurate 
endoscopic size estimation in UD-EGCs is well noted in 
the studies, because the lesions with size > 20 mm were 
noted in up to 45.5% of  lesions[88]. Particularly, the study 
including intramucosal UD-EGC with size ≤ 20 mm 
regardless of  ulcerations revealed notably higher SM in-
vasion (28.3%), ulcer finding (28.3%), and size > 20 mm 
(51.7%) rates[73]. The overall inaccuracies of  assessment 
of  depth of  invasion, ulcerative findings, and size of  
UD-EGC tumors fulfilling the expanded criteria are not 
negligible, and thus ESD criteria based on endoscopic 
and histologic findings in UD-EGC should have more re-
strictions compared to differentiated EGC. To overcome 
this limitation, new methods beyond the current level of  
technology are strongly needed.
SHORT-TERM OUTCOMES 
In addition to a very low possibility of  LN metastasis, the 
safety of  ESD for UD-EGC can be established based 
on the feasibility of  curative resection with acceptable 
complication rates and consequently favorable long-term 
outcomes. 
Short-term outcomes, including en bloc resection, com-
plete resection, curative resection, and complication rates, 
of  ER for UD-EGC are listed in Table 4[73,74,76,80,87-90]. 
Whereas homogeneous definitions of  en bloc resection 
applied for the studies, the definitions of  complete resec-
tion category were heterogeneous depending on the in-
volvement of  en bloc resection or lymphovascular invasion 
or submucosal invasion[73,74,80,87,90]. Additionally, the defini-
tions of  curative resection in some studies did not clarify 
the involvement of  en bloc resection[80,89,90]. The overall 
rates of  en bloc resection, complete resection, and curative 
resection of  ER for UD-EGCs varied from 83.1% to 
100%, from 55.0% to 90.7%, and from 31.1% to 82.5%, 
respectively, while those of  ESD for UD-EGCs meet-
ing the expanded criteria ranged from 91.3% to 99.0%, 
from 89.7% to 90.7%, and from 63.9% to 82.5%, respec-
Table 3  Clinical characteristics of representative studies on endoscopic resection for undifferentiated type early gastric cancer
Study Year Country No. of patients 
with UD-EGC
No. of patients 
with PD/SRC
Age (yr)1 Sex (male) SM invasion Ulcer Size (mm)1 Size > 20 mm
Kim et al[80] 2013 South Korea  74 55/19 61.8 ± 12.0 40 (54.1)   16 (21.6) 11 (14.9)   19.9 ± 12.5 36 (48.6)
Abe et al[87] 2013 Japan  97 18/77/22 62.0 (35.0-88.0)3 55 (56.7)   19 (19.6) 9 (9.3) 12.03 14 (14.4)
Park et al[88] 2012 South Korea  77  47/154 60.9 (33.0-82.0) 49 (63.6)   12 (15.6) 4 (5.2)   23.3 ± 14.0 35 (45.5)
Okada et al[89] 2012 Japan 1035 12/91 59.0 (34.0-91.0) 48 (46.6) 10 (9.7) 1 (1.0) 8.0 (1.0-33.0)3 NA
Kamada et al[76] 2012 Japan  46 NA 65.5 (29.0-90.0) 24 (52.2)     7 (15.2) 1 (2.2) NA   8 (17.4)
Yamamoto et al[90] 2010 Japan  58 48/10 64.0 (33.0-81.0) 31 (53.4)     7 (12.1) 2 (3.4) 11.0 (2.0-28.0) 5 (8.6)
Kang et al[73] 2010 South Korea  60 30/30 56.7 ± 10.4 31 (51.7)   17 (28.3) 17 (28.3)   26.3 ± 12.9 31 (51.7)
Kim et al[74] 2009 South Korea  58 17/41 55.0 (26.0-81.0) 26 (44.8) NA   0 (0) 13.3 ± 6.5 4 (6.9)
Data are expressed as absolute numbers (percentage) or mean ± SD. 1Data are expressed as mean with standard deviation or range; 2Two patients had EGCs 
with histology of moderately to poorly differentiated adenocarcinoma; 3Data are expressed as median with or without range; 4Fifteen patients had EGCs 
with mixed type histology; 5A total of 103 EGCs in 101 patients were enrolled. UD-EGC: Undifferentiated typr early gastric cancer; PD: Poorly-differentiat-
ed adenocarcinoma; SRC: Signet-ring cell carcinoma; SM: Submucosa; NA: Not available.
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tively[76,87,89,90]. The results of  ESD for cases within the 
expanded criteria were comparable with the outcomes 
of  ESD for differentiated EGCs fulfilling the criteria 
of  93.0% to 95.7% and 81.0% to 91.1% for en bloc and 
complete resection rates, respectively[91-93]. In contrast, the 
curative resection rate seems to be lower than that of  dif-
ferentiated EGCs, which is 91.1%[93]. This may arise from 
less accurate endoscopic size estimation in UD-EGC due 
to an ill-defined margin of  tumor infiltration[41,94,95] and 
several distinct features of  UD-EGC, including a larger 
size and submucosal infiltration that can lead to higher 
rates of  lymphovascular invasion[73,82,90,96-98], compared 
with EGCs with differentiated histology. Therefore, the 
achievement of  reasonable curative resection rate in ESD 
for UD-EGC is critical by means of  more precisely de-
fining of  curable lesions. 
Further surgical treatments were performed in 26.2% 
to 60.0% of  patients with incomplete or non-curative 
ER. The presence of  residual tumor and LN metastasis 
in surgical specimens after incomplete or non-curative 
ER were detected in 4.8% to 44.4% and 0% to 13.3% 
of  cases. The overall rates of  bleeding and perforation 
varied from 1.4% to 13.8% and from 1.0% to 4.3%, 
respectively, whereas those of  ESD for UD-EGCs meet-
ing the expanded criteria ranged from 4.1% to 8.7% and 
from 1.0% to 4.3%, respectively. The results from lesions 
within the criteria were comparable with the bleeding 
and perforation rates of  ESD for differentiated EGCs 
fulfilling the criteria, which were 2.1% to 4.9% and 2.4% 
to 6.6%, respectively[91-93]. In terms of  procedure-related 
complications, ESD for UD-EGC appears not to be infe-
rior to ESD for EGC with differentiated histology. 
LONG-TERM OUTCOMES 
Only limited data are available regarding long-term out-
comes of  ESD for UD-EGC[51,80,87,89], although the recur-
rences after ER have been shown in 0% to 6.9% with fol-
low-up durations ranging from 16 to 45.6 mo[73,74,76,88,90]. 
Okada et al[89] reported the first study regarding long-term 
outcomes of  ESD for UD-EGC with limited median 
follow-up periods. The 5-year cause-specific survival rate 
among 78 patients with curative resection of  UD-EGC 
was 100%, which was as high as the reported data for 
gastrectomy[99,100]; however, the median follow-up period 
was only 36 mo. The cumulative 3- and 5-year disease-
free survival rates are 96.7% (95%CI: 92.0%-100%) and 
96.7% (95%CI: 92.0%-100%), respectively. During the 
follow-up period, all patients survived, and no cases of  
local recurrence and/or distant metastasis were observed. 
There were only second ESDs for one synchronous le-
sion of  one patient 6 mo after the primary ESD (1/78, 
1.3%) and two metachronous lesions of  another patient 
after 23 mo (1/78, 1.3%).
Abe et al[87] analyzed the overall 5-year survival of  
79 UD-EGC patients that underwent ESD, while they 
enrolled 97 patients for short-term outcomes analyses. 
Of  the 46/79 patients in the long-term outcome group 
who had curative resection, none had local recurrence or 
LN or distant metastasis, and none died of  gastric cancer 
during a median follow-up of  76.4 mo. The 5-year overall 
survival rate after curative resection was 93.0%, and no 
patient died of  gastric cancer. These favorable results are 
comparable to long-term outcomes of  those who un-
derwent ESD for differentiated EGC and surgery for in-
tramucosal gastric cancer, which have the overall survival 
rates of  92.4% to 97.1%[101-103] and 93.5%[104], respectively. 
The 5-year cumulative incidence of  metachronous gastric 
cancer was 11.4% in the patients with curative resection 
and they were treated with ESD. 
Kim et al[80] reported consistent results showing a local 
recurrence rate of  5.5% and a 5-year overall survival rate 
of  93.7% among 74 enrolled patients with median fol-
low-up period of  34 mo (range 7-81 mo). All 4 recurred 
lesions did not meet the expanded indications and all 
underwent noncurative resection. There was no mortality 
related to ESD for treatment of  EGC during follow-up, 
whereas a total of  five patients died after ESD due to un-
derlying diseases (four patients) and lung metastasis (one 
patient).
The questionnaire study on long-term outcomes of  
curative ESD for EGC at six Japanese institutions with 
follow-up rates of  at least 90% over a minimum 5-year 
period was reported by Oda et al[51]. Of  a total of  1289 
patients with curative resections for the expanded in-
dications, the long-term outcomes of  58 patients with 
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Table 4  Short-term outcomes of endoscopic resection for undifferentiated early gastric cancer  n  (%)
Study LMP VMP LVI En bloc  
resection
Complete 
resection
Curative 
resection
OP after ER1 Residual 
tumor2
LNM2 Bleeding Perforation
Kim et al[80] NA NA 10 (12.5)   67 (90.5) 54 (73.0) 23 (31.1) 19/51 (37.3) NA NA    1 (1.4) 3 (4.1)
Abe et al[87] 5 (5.2) 4 (4.1) 3 (3.1)   96 (99.0) 88 (90.7) 62 (63.9) 21/35 (60.0)  1/21 (4.8) 2/21 (9.5)    4 (4.1) 4 (4.1)
Park et al[88] 12 (15.6)3 5 (6.5)   64 (83.1) NA 35 (45.5) 11/42 (26.2) NA 0/11 (0.0) NA NA
Okada et al[89] 5 (4.9)3 2 (2.0) 102 (99.0) NA 85 (82.5) 10/18 (55.6) 2/10 (20.0) 0/10 (0.0)    9 (8.7) 1 (1.0)
Kamada et al[76]   5 (10.9) 4 (8.7) 4 (8.7)   42 (91.3) NA NA 5   1/5 (20.0) NA 2/46 (4.3) 2 (4.3)
Yamamoto et al[90] 1 (1.7) 0 (0.0) 2 (3.4)   57 (98.3) 52 (89.7) 46 (79.3)   8/12 (66.7)   2/8 (25.0) 0/8 (0.0)    5 (8.6) 2 (3.4)
Kang et al[73] 14 (23.3) 11 (18.3) 15 (25.0)  60 (100) 33 (55.0) NA 15/27 (55.6) 6/15 (40.0) 2/15 (13.3)    1 (1.7) 1 (1.7)
Kim et al[74] 10 (52.6)   9 (47.4) NA   49 (84.5) 39 (67.2) NA   9/19 (47.4)   4/9 (44.4)   1/9 (11.1)      8 (13.8) 1 (1.7)
1Proportions are ratio of additional operation to incomplete or non-curative endoscopic resection; 2Data are the incidence of residual tumor or lymph node 
metastasis in specimens obtained by additional operation; 3Data are cases with lateral and/or vertical margin positivity. LMP: Lateral margin positivity; 
VMP: Vertical margin positivity; LVI: Lymphovascular invasion; OP: Operation; ER: Endoscopic resection; LNM: Lymph node metastasis; NA: Not available.
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intramucosal UD-EGC ≤ 20 mm in size without ulcer-
ations were analyzed, and 96.6% of  them (56/58) were 
followed up for at least 5 years. The overall mortality rate 
was 10.7% (6/56), and there was no local recurrence, or 
distant metastasis, or gastric cancer-related death during 
their long-term follow-up periods.
In addition to the 5-year survival outcomes, the long-
term data on metachronous EGCs after ESD for UD-
EGC are also lacking. The cumulative incidences of  
metachronous lesions varied from 1.3% to 11.4% dur-
ing median follow-up periods with a range of  36-76.4 
mo[87-89]. This finding is comparable to the annual inci-
dences of  metachronous lesions after ESD for differ-
entiated EGC, which ranged from 1.9% to 3.9%[105,106] 
as well as reports of  remnant gastric cancers occurring 
in 1.8% to 5% of  patients who have had surgical treat-
ment for gastric cancer[107,108]. Therefore, careful periodic 
endoscopic surveillance should be performed, because 
UD histology is a possible risk factor associated with the 
occurrence of  metachronous lesions after ER[109]. Al-
though the clinical importance of  scheduled endoscopic 
surveillance after curative resection are recently evalu-
ated through large-volume multicenter study[110], further 
studies on surveillance follow-up after curative ESD for 
UD-EGC, compared with curative cases in differentiated 
EGC, are warranted.
PROSPECTS FOR THE FUTURE
A combination of  laparoscopic sentinel node biopsy 
and ESD for UE-EGC is an attractive option as a novel, 
whole stomach-preserved, minimally invasive approach 
with histological confirmation of  LN metastasis. How-
ever, a number of  technical controversies should be 
resolved to accept the laparoscopic sentinel node map-
ping and consequent intraoperative ESD as an acceptable 
treatment. These include the accuracy of  intraoperative 
pathological diagnosis, the necessity of  full-thickness re-
section, and the possibility of  cancer cells being present 
in afferent lymphatic vessels leading to sentinel nodes[111]. 
In particular, a well-designed, multicenter feasibility study 
of  laparoscopic sentinel node mapping and biopsy for 
UD-EGC should be conducted, though the accuracy of  
determining LN status by laparoscopic sentinel node bi-
opsy is generally acceptable in cases with EGC[112-114].
Natural orifice transluminal endoscopic surgery 
(NOTES) is another promising area to supplement ESD 
by providing for the means for performing secure gastric 
closure at the time of  the accidental perforation without 
recourse to surgical operation, or as a complement for 
endoscopic sentinel node biopsy[115-117]. The potential 
indications of  NOTES have been suggested with a wide 
spectrum of  upper gastrointestinal diseases, including 
submucosal malignancy and morbid obesity in female pa-
tients[118-120]. Furthermore, the first prospective study of  
14 patients with EGC who had a risk for LN metastasis 
and who were treated by hybrid NOTES was reported 
and suggested that hybrid NOTES may be useful as a 
bridge between ER and laparoscopic surgery[121]. Never-
theless, given the relatively technical complexity and lim-
its, NOTES has not been proven to remarkably superior 
to laparoscopic means so far.
CONCLUSION
Based on the results of  studies on short- and long-term 
Undifferentiated histologic type EGC
Mucosal cancer Submucosal cancer
Tumor size ≤ 20 mm Tumor size > 20 mm
Ulcer (-) Ulcer (+)
ESD
LVI (-) LVI (+)
Follow up Surgery (gastrectomy and lymph node dissection)
Figure 2  Treatment algorithm for undifferentiated type early gastric cancer according to depth of invasion, tumor size, ulceration, and lymphovascular 
invasion. EGC: Early gastric cancer; ESD: Endoscopic submucosal dissection; LVI: Lymphovascular invasion.
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outcomes, the expanded criteria for ESD of  UD-EGC 
are feasible with reference to therapeutic efficacy and 
safety in the long-term period if  curative resection is 
accomplished, although more long-term outcomes are 
needed. We now suggest the treatment algorithm for 
UD-EGC according to depth of  invasion, tumor size, 
ulceration, and lymphovascular invasion (Figure 2). This 
is consistent with the conditions of  curative resection 
according to the Japanese gastric cancer treatment guide-
lines[23,26]. However, we should recognize the limitation 
of  current diagnostic and histological tools to predict LN 
metastasis. The innovative improvement of  preoperative 
imaging modalities and well-defined criteria predictive 
of  LN metastasis from multicenter, prospective studies 
would reduce the limitation.
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